| pubmed-article:21845209 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:21845209 | lifeskim:mentions | umls-concept:C0006142 | lld:lifeskim |
| pubmed-article:21845209 | lifeskim:mentions | umls-concept:C0012634 | lld:lifeskim |
| pubmed-article:21845209 | lifeskim:mentions | umls-concept:C0034897 | lld:lifeskim |
| pubmed-article:21845209 | lifeskim:mentions | umls-concept:C0205276 | lld:lifeskim |
| pubmed-article:21845209 | lifeskim:mentions | umls-concept:C1514475 | lld:lifeskim |
| pubmed-article:21845209 | lifeskim:mentions | umls-concept:C0439792 | lld:lifeskim |
| pubmed-article:21845209 | pubmed:dateCreated | 2011-8-16 | lld:pubmed |
| pubmed-article:21845209 | pubmed:abstractText | Despite improvements of the therapy for breast cancer, a proportion of the patients still get local recurrence. The status of the surgical margins is the most often used parameter for decision regarding additional treatment. However, a negative margin is not a guarantee that there is not residual cancer left in the breast; additional parameters are needed to better predict the risk of local recurrence. The disease extent was evaluated in the surgical specimen from 313 women after breast-conserving therapy using large-section histology and was correlated to the incidence of local recurrence. A disease extent ?4?cm was shown to be an independent marker for local recurrence; the cumulative 10-year local relapse rate for the group with a disease extent ?4?cm was 20.5%, and for the rest 6.7%. We conclude that disease extent ?4?cm seems to be an important factor when evaluating the risk for local recurrence. | lld:pubmed |
| pubmed-article:21845209 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21845209 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21845209 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21845209 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21845209 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21845209 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21845209 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21845209 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21845209 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21845209 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21845209 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21845209 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21845209 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21845209 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21845209 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21845209 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21845209 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21845209 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21845209 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21845209 | pubmed:language | eng | lld:pubmed |
| pubmed-article:21845209 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21845209 | pubmed:status | PubMed-not-MEDLINE | lld:pubmed |
| pubmed-article:21845209 | pubmed:issn | 2042-003X | lld:pubmed |
| pubmed-article:21845209 | pubmed:author | pubmed-author:LindquistDD | lld:pubmed |
| pubmed-article:21845209 | pubmed:author | pubmed-author:HellbergDD | lld:pubmed |
| pubmed-article:21845209 | pubmed:author | pubmed-author:ToiCC | lld:pubmed |
| pubmed-article:21845209 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:21845209 | pubmed:volume | 2011 | lld:pubmed |
| pubmed-article:21845209 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:21845209 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:21845209 | pubmed:pagination | 860584 | lld:pubmed |
| pubmed-article:21845209 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:21845209 | pubmed:articleTitle | Disease Extent ?4?cm Is a Prognostic Marker of Local Recurrence in T1-2 Breast Cancer. | lld:pubmed |
| pubmed-article:21845209 | pubmed:affiliation | Department of Pathology and Clinical Cytology, Central Hospital Falun, SE-791 82 Falun, Sweden. | lld:pubmed |
| pubmed-article:21845209 | pubmed:publicationType | Journal Article | lld:pubmed |
